Table 1:

Patient clinical data including underlying epilepsy syndrome, seizure type, and antiepileptic medications

PatientAge (yr)Epilepsy Syndrome2123Seizure TypeMedications
11EE (Unclassified)TLEV
22Metabolic (Mito)TSZNS/LTG/LEV
27Metabolic (Mito)TS/GTCZNS/LTG/LEV/RFM
28Metabolic (Mito)TS/MY/GTCZNS/LTG/LEV/RFM
47Metabolic (Mito)MY/RFLTPM
410Metabolic (Mito)MY/RFLTPM/ZNS
62Structural (MCD)FocalZNS/TPM
71Structural (Aicardi)ESVGB
96Metabolic (Mito)MY/ATLEV/LTG/ETX/CLN
110.5Genetic (ATP1A3)Focal/SELEV
111Genetic (ATP1A3)SUB/MYLTG/CLB
126EE (unclassified)AT/T/GTCCLB
131EE (unclassified)ESVGB
142Metabolic (Mito)ESTPM
161EE (Unclassified)ESZNS/LEV
175Genetic (DEAF 1)T/AT/GTCLEV
181Metabolic (Mito)ESZNS
  • Note:—“Epilepsy Syndrome”: EE indicates epileptic encephalopathy; Mito, primary mitochondrial disease; MAE, myoclonic astatic epilepsy; MCD, malformation of cortical development; LGS, Lennox-Gastaut Syndrome; “Seizure Type”: T, tonic; TS, tonic spasms; GTC, generalized tonic-clonic; MY, myoclonic; AT, atonic; RFL, reflexive seizure; ES, epileptic spasms; SE, status epilepticus; AA, atypical absence; SUB, subclinical seizures; “Medications”: LEV, levetiracetam; ZNS, zonisamide; LTG, lamotrigine; RFM, rufinamide; CLB, clobazam; TPM, topiramate; VGB, vigabatrin; ETX, ethosuximide; CLN, clonazepam; VPA, valproic acid.